Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.35 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.35 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8522251 | 0.87 | PARP1 (0.43) | PARP1HTR6IDO1SLC6A4MEN1 | |
| SCHEMBL144025 | 0.85 | PARP1 (0.50) | PARP1FLT3MEN1ALDH1A1PRNP | |
| SCHEMBL8622177 | 0.79 | ACVR1 (0.46) | PARP1FLT3MEN1ALDH1A1PRNP | |
| SCHEMBL1584889 | 0.79 | PIM1 (0.56) | IDO1FLT3MEN1ALDH1A1PRNP | |
| SCHEMBL1507612 | 0.78 | PARP1 (0.54) | PARP1IDO1MEN1ALDH1A1HPGD | |
| SCHEMBL8700858 | 0.78 | PARP1 (0.54) | PARP1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2191063 | 0.78 | PARP1 (0.54) | PARP1HTR1AIDO1ALDH1A1HTT | |
| SCHEMBL2574527 | 0.78 | LMNA (0.57) | PARP1HTR1AHTR7HTR6SLC6A4 | |
| SCHEMBL2191001 | 0.78 | PARP1 (0.54) | PARP1IDO1FLT3ALDH1A1HPGD | |
| SCHEMBL9514887 | 0.75 | IP6K1 (0.41) | PARP1FLT3MEN1ALDH1A1PRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111072576-A | Preparation method of lapatinib key intermediate | 南京奇可药业有限公司 | 2020-04-28 | — | — | CN | claimed |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-21 | — | — | US | disclosed |
| CN-111072576-A | Preparation method of lapatinib key intermediate | 南京奇可药业有限公司 | 2020-04-28 | — | — | CN | disclosed |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| US-9994529-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-9604938-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| EP-2744501-B1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20030055049-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-6465449-B1 | SUCH AS (6-(4-(6-AMINO-3-AZA-BICYCLO(3.1.0)HEX-3-YLMETHYL)-PHENYL)-QUINAZOLIN-4-YL) -(4-PHENOXY-PHENYL)-AMINE | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| CN-1333758-A | Substituted bicyclic derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| EP-1029853-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | PARP1 822/4885HTR1A 1337/4885HTR7 1195/4885 |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | PARP1 822/4885HTR1A 1337/4885HTR7 1195/4885 |
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | PARP1 1602/4885HTR1A 2022/4885HTR7 972/4885 |
| US-20030055049-A1 | Heteroaromatic bicyclic derivatives useful as anticancer agents | RCC1, CCNA1, MCL1 | PARP1 386/4885HTR1A 1822/4885HTR7 3375/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | PARP1 325/4885HTR1A 3357/4885HTR7 4261/4885 |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | PARP1 822/4885HTR1A 1337/4885HTR7 1195/4885 |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | ABL1, MAP3K3, MAP4K2 | PARP1 822/4885HTR1A 1337/4885HTR7 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.